Analysts expect Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) to report $29.79 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s earnings, with the lowest sales estimate coming in at $25.84 million and the highest estimate coming in at $33.73 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share posted sales of $43.09 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 30.9%. The firm is expected to report its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will report full year sales of $29.79 million for the current fiscal year, with estimates ranging from $165.43 million to $173.32 million. For the next year, analysts expect that the business will post sales of $111.38 million per share, with estimates ranging from $105.03 million to $117.72 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share.

A number of brokerages have recently issued reports on AVDL. Roth Capital set a $14.00 target price on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the company a “buy” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Zacks Investment Research lowered Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research report on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $21.50.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ AVDL) opened at $8.99 on Wednesday. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 52-week low of $7.52 and a 52-week high of $12.30. The stock has a market capitalization of $369.98, a P/E ratio of 4.66 and a beta of 1.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.47 and a current ratio of 1.53.

In other news, CEO Michael S. Anderson acquired 5,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were bought at an average price of $8.86 per share, for a total transaction of $44,300.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Craig R. Stapleton acquired 140,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was purchased at an average price of $8.67 per share, for a total transaction of $1,213,800.00. The disclosure for this purchase can be found here. Company insiders own 5.07% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its holdings in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after purchasing an additional 10,532 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 3rd quarter valued at $132,000. Arrowstreet Capital Limited Partnership purchased a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 2nd quarter valued at $181,000. Cubist Systematic Strategies LLC purchased a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 3rd quarter valued at $184,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the 3rd quarter valued at $205,000. Institutional investors own 64.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/14/29-79-million-in-sales-expected-for-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-this-quarter.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.